Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
Phase 2
Completed
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: ChAdOx-1-S[recombinant]Biological: AVX-COVID/12
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
- Target Recruit Count
- 4065
- Registration Number
- NCT05710783
- Locations
- 🇲🇽
Clinical Research Institute S.C., Tlalnepantla, Estado De México, Mexico
🇲🇽Centro Multidisciplinario para el Desarrollo Especializado de la Investigación Clinica en Yucatán S.C.P., Mérida, Yucatán, Mexico
🇲🇽Unidad de Atención Médica e Investigación en Salud, S.C.P., Mérida, Yucatán, Mexico
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
Phase 2
Completed
- Conditions
- SARS CoV 2 Infection
- Interventions
- Biological: PlaceboBiological: Recombinant NDV Vectored Vaccine for SARS-CoV-2
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
- Target Recruit Count
- 158
- Registration Number
- NCT05205746
- Locations
- 🇲🇽
Centro Mexicano de Estudios Clínicos CEMDEC SA de CV, Mexico City, Cdmx, Mexico
🇲🇽Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro Social, Mexico City, Cdmx, Mexico
🇲🇽CAIMED Investigación en Salud S.A. de C.V., Mexico City, Cdmx, Mexico
Study of a Live rNDV Based Vaccine Against COVID-19
Phase 1
Completed
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: Recombinant NDV Vectored Vaccine for SARS-CoV-2
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
- Target Recruit Count
- 91
- Registration Number
- NCT04871737
- Locations
- 🇲🇽
Hospital Medica Sur, Mexico City, Ciudad De Mexico, Mexico
© Copyright 2025. All Rights Reserved by MedPath